Prevalence and Risk Factors of Nonalcoholic Fatty Liver Disease in Breast Cancer Patients

Abstract

Aims and background

We aimed to evaluate the prevalence of nonalcoholic fatty liver disease (NAFLD) in breast cancer patients using liver magnetic resonance imaging (MRI), and to investigate factors associated with NAFLD.

Methods

We evaluated 104 patients surgically treated for breast cancer at our hospital between September and November 2013. None of the patients had any other causes of secondary hepatic fat accumulation (such as signiﬁcant alcohol consumption, use of steatogenic medication or inborn disorders). Hepatic fat accumulation was measured using liver MRI perfomed in all patients before surgical treatment.

Results

Based on the fat signal percentage from liver MRIs, 19 of 104 breast cancer patients were diagnosed with NAFLD, so the prevalence of NAFLD was 18.3%. In univariate analysis, factors associated with NAFLD were older age, high body mass index, type 2 diabetes mellitus (DM), hypertension, elevated aspartate aminotransferase, elevated alanine aminotransferase and elevated triglycerides (TG). In multivariate analysis, factors associated with NAFLD were high body mass index (BMI) (odds ratio [OR] 1.403; 95% confidence interval [CI] 1.111-1.771; p = 0.005), type 2 DM (OR 11.872; 95% CI 1.065-132.373; p = 0.044), and an elevated TG level (OR 50.267; 95% CI 4.409-573.030; p = 0.002).

Conclusions

The prevalence of NAFLD in breast cancer patients was not different from that of the general population. High BMI, type 2 DM and an elevated serum TG level were factors associated with NAFLD.

Get full access to this article

View all access options for this article.

References

Chalasani

Younossi

Lavine

et al; American Gastroenterological Association; American Association for the Study of Liver Diseases; American College of Gastroenterology. The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology. Gastroenterology. 2012;142 (7):1592–1609.

Shaker

Tabbaa

Albeldawi

Alkhouri

Liver transplantation for nonalcoholic fatty liver disease: new challenges and new opportunities. World J Gastroenterol. 2014;20 (18):5320–5330.

van Werven

Marsman

Nederveen

Assessment of hepatic steatosis in patients undergoing liver resection: comparison of US, CT, T1-weighted dual-echo MR imaging, and point-resolved 1H MR spectroscopy. Radiology. 2010;256 (1):159–168.

Eliassen

Colditz

Rosner

Willett

Hankinson

Adult weight change and risk of postmenopausal breast cancer. JAMA. 2006;296 (2):193–201.

Emaus

van Gils

Bakker

Weight change in middle adulthood and breast cancer risk in the EPIC-PANACEA study. Int J Cancer. 2014;135 (12):2887–2899.

Kim

Lee

W-Y

Kang

J-H

et al; Committee of Clinical Practice Guidelines; Korean Society for the Study of Obesity. 2014 Clinical practice guidelines for overweight and obesity in Korea. Endocrinol Metab (Seoul). 2014;29 (4):405–409.

Qayyum

Goh

Kakar

Yeh

Merriman

Coakley

Accuracy of liver fat quantification at MR imaging: comparison of out-of-phase gradient-echo and fat-saturated fast spin-echo techniques—initial experience. Radiology. 2005;237 (2):507–511.

Rinella

McCarthy

Thakrar

Dual-echo, chemical shift gradient-echo magnetic resonance imaging to quantify hepatic steatosis: implications for living liver donation. Liver Transpl. 2003;9 (8):851–856.

Zelber-Sagi

Nitzan-Kaluski

Halpern

Oren

Prevalence of primary non-alcoholic fatty liver disease in a population-based study and its association with biochemical and anthropometric measures. Liver Int. 2006;26 (7):856–863.

10.

Clark

The epidemiology of nonalcoholic fatty liver disease in adults. J Clin Gastroenterol. 2006;40 (Suppl 1):S5–S10.

11.

Clark

Diehl

Nonalcoholic fatty liver disease: an underrecognized cause of cryptogenic cirrhosis. JAMA. 2003;289 (22):3000–3004.

12.

Chitturi

Farrell

Hashimoto

Saibara

Lau

Sollano

Asia-Pacific Working Party on NAFLD. Non-alcoholic fatty liver disease in the Asia-Pacific region: definitions and overview of proposed guidelines. J Gastroenterol Hepatol. 2007;22 (6):778–787.

13.

Kim

Clinical and metabolic factors associated with development and regression of nonalcoholic fatty liver disease in nonobese subjects. Liver Int. 2014;34 (4):604–611.

14.

McCullough

The clinical features, diagnosis and natural history of nonalcoholic fatty liver disease. Clin Liver Dis. 2004;8 (3):521–533, viii.

15.

Singh

Allen

Wang

Prokop

Murad

Loomba

Fibrosis progression in nonalcoholic fatty liver vs nonalcoholic steatohepatitis: a systematic review and meta-analysis of paired-biopsy studies. Clin Gastroenterol Hepatol. 2015;13 (4):643–654.e1–e9, quiz e39-e40.

16.

Torres

Williams

Harrison

Features, diagnosis, and treatment of nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol. 2012;10 (8):837–858.

17.

Kim

Younossi

Nonalcoholic fatty liver disease: a manifestation of the metabolic syndrome. Cleve Clin J Med. 2008;75 (10):721–728.

18.

Rector

Thyfault

Wei

Ibdah

Non-alcoholic fatty liver disease and the metabolic syndrome: an update. World J Gastroenterol. 2008;14 (2):185–192.

19.

Adams

Lymp

St Sauver

The natural history of nonalcoholic fatty liver disease: a population-based cohort study. Gastroenterology. 2005;129 (1):113–121.

20.

Cassidy

Yokoo

Aganovic

Fatty liver disease: MR imaging techniques for the detection and quantification of liver steatosis. Radiographics. 2009;29 (1):231–260.

21.

Roldan-Valadez

Favila

Martínez-López

Uribe

Méndez-Sánchez

Imaging techniques for assessing hepatic fat content in nonalcoholic fatty liver disease. Ann Hepatol. 2008;7 (3):212–220.

22.

Strauss

Gavish

Gottlieb

Katsnelson

Interobserver and intraobserver variability in the sonographic assessment of fatty liver. AJR Am J Roentgenol. 2007;189 (6):W320–W323.

23.

Charatcharoenwitthaya

Lindor

Role of radiologic modalities in the management of non-alcoholic steatohepatitis. Clin Liver Dis. 2007;11 (1):37–54, viii.

24.

Joy

Thava

Scott

Diagnosis of fatty liver disease: is biopsy necessary?

Eur J Gastroenterol Hepatol. 2003;15 (5):539–543.

25.

Castera

Non-invasive diagnosis of steatosis and fibrosis. Diabetes Metab. 2008;34 (6 Pt 2):674–679.

26.

Fishbein

Stevens

Rapid MRI using a modified Dixon technique: a non-invasive and effective method for detection and monitoring of fatty metamorphosis of the liver. Pediatr Radiol. 2001;31 (11):806–809.

27.

Adams

Angulo

Lindor

Nonalcoholic fatty liver disease. CMAJ. 2005;172 (7):899–905.

28.

Machado

Marques-Vidal

Cortez-Pinto

Hepatic histology in obese patients undergoing bariatric surgery. J Hepatol. 2006;45 (4):600–606.

29.

Targher

Day

Bonora

Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease. N Engl J Med. 2010;363 (14):1341–1350.

30.

Bruno

Maisonneuve

Castellana

Incidence and risk factors for non-alcoholic steatohepatitis: prospective study of 5408 women enrolled in Italian tamoxifen chemoprevention trial. BMJ. 2005;330 (7497):932.